- Home
- MHLD vs GALT Comparison
MHLD vs GALT Comparison
Compare MHLD & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHLD
- GALT
- Stock Information
- Founded
- MHLD 2007
- GALT 2000
- Country
- MHLD Bermuda
- GALT United States
- Employees
- MHLD N/A
- GALT N/A
- Industry
- MHLD Property-Casualty Insurers
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- MHLD Finance
- GALT Health Care
- Exchange
- MHLD Nasdaq
- GALT Nasdaq
- Market Cap
- MHLD 159.6M
- GALT 147.8M
- IPO Year
- MHLD 2008
- GALT N/A
- Fundamental
- Price
- MHLD $1.35
- GALT $2.12
- Analyst Decision
- MHLD
- GALT Strong Buy
- Analyst Count
- MHLD 0
- GALT 1
- Target Price
- MHLD N/A
- GALT $11.00
- AVG Volume (30 Days)
- MHLD 114.6K
- GALT 549.5K
- Earning Date
- MHLD 11-12-2024
- GALT 11-13-2024
- Dividend Yield
- MHLD N/A
- GALT N/A
- EPS Growth
- MHLD N/A
- GALT N/A
- EPS
- MHLD N/A
- GALT N/A
- Revenue
- MHLD $89,074,000.00
- GALT N/A
- Revenue This Year
- MHLD N/A
- GALT N/A
- Revenue Next Year
- MHLD N/A
- GALT N/A
- P/E Ratio
- MHLD N/A
- GALT N/A
- Revenue Growth
- MHLD 20.80
- GALT N/A
- 52 Week Low
- MHLD $1.19
- GALT $1.56
- 52 Week High
- MHLD $2.52
- GALT $4.27
- Technical
- Relative Strength Index (RSI)
- MHLD 37.38
- GALT 39.78
- Support Level
- MHLD $1.32
- GALT $1.80
- Resistance Level
- MHLD $1.42
- GALT $2.36
- Average True Range (ATR)
- MHLD 0.10
- GALT 0.23
- MACD
- MHLD -0.02
- GALT -0.03
- Stochastic Oscillator
- MHLD 9.09
- GALT 26.89
About MHLD Maiden Holdings Ltd.
Maiden Holdings Ltd provides reinsurance products and services to regional and specialty property and casualty insurers. The company operates in two segments: AmTrust Reinsurance and Diversified Reinsurance. The AmTrust Reinsurance segment provides products that cover workers' compensation, commercial package, commercial auto, and extended warranty. The Diversified Reinsurance segment provides small and midsize regional and specialty insurers with reinsurance capital products. Its revenues also include fee income earned from both its GLS business and IIS business as well as income generated from its investment portfolio.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.